

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
AVRAMIS ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/02029

FILED: 27 FEBRUARY 2003

U.S. APPLICATION NO: 10/505,399

35 USC §371 DATE: 19 AUGUST 2004

FOR: COMBINATIONS OF (A) AN ATP-COMPETITIVE INHIBITOR OF C-  
ABL KINASE ACTIVITY WITH (B) TWO OR MORE OTHER  
ANTINEOPLASTIC AGENTS

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449, which was previously submitted with our Information Disclosure Statement dated February 28, 2007. The Examiner states in the Office Action dated February 1, 2008 that Applicants failed to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document, each non-patent literature publication or that portion which caused it to be listed. The Office Action states further that the information disclosure statement has been placed in the application file, but the information referred to therein has not been considered.

Applicants respectfully submit that all these references were listed in the International Search Report and the Notice of Acceptance states that the references cited in the ISR were received at the US Patent and Trademark Office on August 19, 2004. Therefore, Applicants were under the impression that it was not required to send these references, which WIPO had already supplied to the United States Patent Office.

However, in order to comply with the Examiner's request, attached is a 1449 Form and copies of all the references cited.

It is believed that no fee is required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824

Respectfully submitted,



George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593

Date: 08-28-08